| Drug General Information |
| Drug ID |
D09GDD
|
| Former ID |
DNAP001694
|
| Drug Name |
Regorafenib
|
| Drug Type |
Small molecular drug
|
| Indication |
Metastatic colorectal cancer [ICD9: 153, 154; ICD10:C18-C21]
|
Approved |
[1],
[2]
|
|---|
| Company |
Bayer HealthCare Pharmaceuticals
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C21H15ClF4N4O3
|
| InChI |
InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)
|
| InChIKey |
FNHKPVJBJVTLMP-UHFFFAOYSA-N
|
| CAS Number |
CAS 755037-03-7
|
| PubChem Compound ID |
|
| PubChem Substance ID |
16247148, 23360295, 42222352, 75430857, 99437016, 123055398, 124757057, 124772081, 125163861, 126731249, 131480720, 135261819, 135626856, 135727382, 136367351, 136368060, 136920288, 136937804, 136967459, 137245314, 137275982, 142611634, 144115687, 152090526, 152258021, 152258178, 152344131, 160645781, 160647014, 162011543, 162037486, 163698233, 164041884, 164764796, 172087026, 172093559, 174530361, 175267155, 175427139, 178102514, 186014501, 188899566, 198992717, 223381220, 223498454, 223565986, 223680722, 223704854, 223925935, 226756197
|
| ChEBI ID |
ChEBI:68647
|
| SuperDrug ATC ID |
L01XE21
|
| Target and Pathway |
| Target(s) |
Proto-oncogene tyrosine-protein kinase receptor ret |
Target Info |
Modulator |
[3]
|
|---|
| Vascular endothelial growth factor receptor 2 |
Target Info |
Modulator |
[3]
|
| Mast/stem cell growth factor receptor |
Target Info |
Modulator |
[3]
|
|
KEGG Pathway
|
Endocytosis
|
|
Pathways in cancer
|
|
Thyroid cancer
|
|
Central carbon metabolism in cancerhsa04014:Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Proteoglycans in cancerhsa04014:Ras signaling pathway
|
|
Hematopoietic cell lineage
|
|
Melanogenesis
|
|
Acute myeloid leukemia
|
|
Central carbon metabolism in cancer
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_15:IL3 Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
KitReceptor Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
Signaling events regulated by Ret tyrosine kinase
|
|
Posttranslational regulation of adherens junction stability and dissassemblyhif2pathway:HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
VEGF and VEGFR signaling network
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY networkcmyb_pathway:C-MYB transcription factor network
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferationR-HSA-1257604:PIP3 activates AKT signaling
|
|
Regulation of KIT signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Dopaminergic NeurogenesisWP306:Focal Adhesion
|
|
Nifedipine Activity
|
|
Cardiac Progenitor Differentiation
|
|
Signaling by VEGF
|
|
AngiogenesisWP304:Kit receptor signaling pathway
|
|
Differentiation Pathway
|
|
Signaling by SCF-KIT
|
|
PIP3 activates AKT signaling
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
| References |
| REF 1 | Nat Rev Drug Discov. 2013 Feb;12(2):87-90. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5891). |
|---|
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
